Vertex Pharma's most recent trend suggests a bullish bias. One trading opportunity on Vertex Pharma is a Bull Put Spread using a strike $75.00 short put and a strike $70.00 long put offers a potential 33.33% return on risk over the next 25 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $75.00 by expiration. The full premium credit of $1.25 would be kept by the premium seller. The risk of $3.75 would be incurred if the stock dropped below the $70.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Vertex Pharma is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Vertex Pharma is bullish.
The RSI indicator is at 52.13 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Vertex Pharma
The Most Important Week of the Year Has Arrived for Gilead Sciences
Tue, 22 Oct 2013 22:34:59 GMT
Motley Fool – Gilead Sciences shareholders and hepatitis C patients should give their full attention to the Food and Drug Administration on Wednesday and Friday.
J&J-Medivir’s Drug Works Against Hepatitis C
Tue, 22 Oct 2013 12:15:44 GMT
Bloomberg – Johnson & Johnson’s and Medivir AB’s experimental hepatitis C treatment is safe and effective, U.S. regulators said, providing a boost to the companies as they try to reach a highly competitive market …
Vertex reports positive results from Phase 2 study of VX-509
Fri, 18 Oct 2013 21:38:43 GMT
theflyonthewall.com – Vertex Pharmaceuticals announced 12-week results from an ongoing Phase 2b study of VX-509, an investigational oral, selective Janus kinase 3 inhibitor, dosed once or twice daily in people with active rheumatoid …
Oral Selective JAK3 Inhibitor VX-509 Showed Statistically Significant Improvements in Signs and Symptoms of Rheumatoid Arthritis After 12 Weeks of Treatment in Phase 2b Study
Fri, 18 Oct 2013 21:36:00 GMT
Business Wire – Vertex Pharmaceuticals Incorporated today announced 12-week results from an ongoing Phase 2b study of VX-509, an investigational oral, selective Janus kinase 3 inhibitor, dosed once or twice daily in people with active rheumatoid arthritis taking methotrexate.
Fri, 18 Oct 2013 11:32:00 GMT
Forbes – Actual bubble, not to be confused with the metaphorical bubble discussed at left. (Photo credit: Wikipedia) For me, one glance was all it took. Looking at my colleague's computer from across the room, I could see that this pre-IPO company's lead oncology asset — presumably the driving force behind this white-hot offering […]
Also on Market Tamer…
Follow Us on Facebook